Evelo Biosciences Inc (EVLO) Receives Average Rating of “Buy” from Brokerages

Shares of Evelo Biosciences Inc (NASDAQ:EVLO) have received a consensus recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $22.75.

Several analysts recently commented on the company. ValuEngine lowered Evelo Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. JMP Securities reissued a “buy” rating and issued a $25.00 price objective on shares of Evelo Biosciences in a research note on Monday, December 3rd. Finally, Chardan Capital reissued a “hold” rating and issued a $10.00 price objective on shares of Evelo Biosciences in a research note on Friday, February 15th.

EVLO stock traded up $0.07 during trading on Wednesday, hitting $8.09. The company had a trading volume of 3,595 shares, compared to its average volume of 30,166. The company has a debt-to-equity ratio of 0.09, a current ratio of 16.43 and a quick ratio of 16.43. The firm has a market cap of $265.16 million and a price-to-earnings ratio of -2.91. Evelo Biosciences has a fifty-two week low of $6.51 and a fifty-two week high of $16.75.

Evelo Biosciences (NASDAQ:EVLO) last announced its quarterly earnings results on Thursday, February 14th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.09. On average, research analysts anticipate that Evelo Biosciences will post -2.48 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the business. Credit Suisse AG raised its position in shares of Evelo Biosciences by 101.8% during the third quarter. Credit Suisse AG now owns 888,287 shares of the company’s stock worth $10,819,000 after acquiring an additional 448,118 shares during the last quarter. BlackRock Inc. raised its position in shares of Evelo Biosciences by 157.5% during the fourth quarter. BlackRock Inc. now owns 670,944 shares of the company’s stock worth $8,729,000 after acquiring an additional 410,407 shares during the last quarter. Vanguard Group Inc raised its position in shares of Evelo Biosciences by 258.0% during the third quarter. Vanguard Group Inc now owns 239,792 shares of the company’s stock worth $2,920,000 after acquiring an additional 172,804 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Evelo Biosciences by 258.0% during the third quarter. Vanguard Group Inc. now owns 239,792 shares of the company’s stock worth $2,920,000 after acquiring an additional 172,804 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Evelo Biosciences by 119.7% during the fourth quarter. Northern Trust Corp now owns 128,155 shares of the company’s stock worth $1,667,000 after acquiring an additional 69,825 shares during the last quarter. 85.05% of the stock is currently owned by institutional investors.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types.

Featured Story: What is intrinsic value?

Analyst Recommendations for Evelo Biosciences (NASDAQ:EVLO)

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.